Provided by Tiger Trade Technology Pte. Ltd.

CKLIFE SCIENCES

0.730
-0.010-1.35%
Volume:1.76M
Turnover:1.29M
Market Cap:7.02B
PE:-37.63
High:0.740
Open:0.740
Low:0.720
Close:0.740
52wk High:1.100
52wk Low:0.640
Shares:9.61B
HK Float Shares:9.61B
Volume Ratio:0.80
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.019
ROE:-5.12%
ROA:-0.72%
PB:1.86
PE(LYR):-37.63
PS:1.30

Loading ...

长江生命科技聚焦医药研发与商业运营,2025年净亏损同比扩大

Bulletin Express
·
Yesterday

CK Life Sciences releases 2025 Sustainability Report, introduces low-carbon transition plan and publishes first Scope 3 emissions

Bulletin Express
·
Yesterday

CK Life Sciences to Seek Shareholder Nod on Director Elections, HK$100,000 Fees and 10% Share Issue/Buy-back Mandates at 21 May 2026 AGM

Bulletin Express
·
Yesterday

CK Life Sciences announces annual general meeting

Reuters
·
Yesterday

CK Life Sciences publishes 2025 annual report

Reuters
·
Yesterday

CK Life Sciences: No Change in Share Capital for March 2026; Public Float Meets 25% Rule

Bulletin Express
·
Apr 02

CK Life Sciences reports 9.61 billion shares outstanding, total voting rights unchanged

Reuters
·
Apr 02

CK Life Sciences’ Sequencio Therapeutics Presents the Latest Vaccine Research Advancements at the American Association for Cancer Research Annual Meeting

THOMSON REUTERS
·
Mar 31

CK Life Sciences’ subsidiary Sequencio to showcase five preclinical cancer vaccine programmes at AACR 2026

Bulletin Express
·
Mar 31

CKLIFE SCIENCES Affiliate to Present Preclinical Data on Cancer Vaccines at AACR 2026

Stock News
·
Mar 31

CK Life Sciences unit Sequencio to present preclinical cancer vaccine data at AACR 2026

Reuters
·
Mar 31

CK Life Sciences Plummets Over 4% Amid Widened Annual Loss and Surging R&D Costs

Stock News
·
Mar 20

BRIEF-CK Life Sciences Intl Logs FY Loss Attributable HK$186.8 Mln

Reuters
·
Mar 17

Revised title

Stock News
·
Mar 17

CK Life Sciences (00775.HK) Annual Loss Widens to HK$186.80 Million in 2025; Revenue Down 2% amid Higher R&D and Vineyard Writedowns

Bulletin Express
·
Mar 17

CK Life Sciences FY2025 loss attributable to shareholders widens 48% to HKD 186.81 million

Reuters
·
Mar 17

CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development

THOMSON REUTERS
·
Mar 10

BRIEF-CK Life Sciences Intl Establishes Sequencio Therapeutics For Cancer Vaccine Development

Reuters
·
Mar 10

CK Life Sciences Forms New Unit to Advance Cancer Vaccine Research

MT Newswires Live
·
Mar 10

CK Life Sciences (00775) Forms Sequencio Therapeutics to Accelerate Cancer Vaccine Pipeline

Bulletin Express
·
Mar 10